Bone marrow mini-allografts (hematology and solid tumors);Les mini-allogreffes de moelle osseuse (hématologie et tumeurs solides)

Bulletin du Cancer

Volumn 88, Issue 1, 2001, Pages 110-113

  Faucher, C ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; BONE MARROW TRANSPLANTATION; CANCER IMMUNOLOGY; CANCER SURGERY; GRAFT VERSUS HOST REACTION; HEMATOLOGY; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; DOGS; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION CONDITIONING;

EID: 0035101920     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Graft-versus-leukemia reactions after bone marrow transplantation
2. Cytokine dysregulation and acute graft-versus-host disease
3. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
4. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias
5. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
6. Identical-twin bone marrow transplants for leukemia
7. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis
8. Long-term follow-up of T-cell depletion for bone marrow transplantation
9. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
10. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
11. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
12. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
13. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia
14. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
15. Bone marrow transplantation for sickle cell disease
16. T-cell depletion of HLA-identical transplants in leukemia
17. Effect of deoxyspergualin on graft-versus-host disease and graft-versus-leukemia in mice
18. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: Preliminary results
19. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
20. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
21. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
22. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
23. Mini-allografts: Ongoing trials in humans
24. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
25. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
26. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
27. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
28. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
29. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
30. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
31. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
32. Mixed chimerism: Preclinical studies and clinical applications